A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Completed · Phase 2, Phase 3 · NCT04206553
Conditions: Bullous Pemphigoid
At a glance
- Research payments reported, 2025
- $960,052
- U.S. investigators named
- 15
- Sites paid
- 13
- Planned or actual enrollment
- 106
About the trial
- Sponsor
- Regeneron Pharmaceuticals (with Sanofi)
- Tested
- dupilumab (drug), Matching Placebo (drug), Oral corticosteroids (OCS) (drug)
- Dates
- Started 2020-10-28; completion 2025-01-05
- Results posted
- Yes
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab i…
From ClinicalTrials.gov, last updated 2026-06-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $960,052 in research payments for this study in 2025 (65 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lauren Graham Dermatology · Birmingham, AL
- Aaron Mangold, M.D. Dermatology · Scottsdale, AZ
- Jun Lu, MD Dermatology · Farmington, CT
- Gil Yosipovitch, MD Dermatology · Miami, FL
- David J. Cohen, MD Dermatology · Macon, GA
- Janet Fairley, MD Dermatology · Iowa City, IA
- David Rosmarin, MD Dermatology · Indianapolis, IN
- Jeffrey M. Sobell, MD Dermatology · Chestnut Hill, MA
- Anna J. Nichols, MD, PHD Dermatology · Damariscotta, ME
- Mio Nakamura, MD Dermatology · Ann Arbor, MI
- Donna A. Culton, MD Dermatology · Chapel Hill, NC
- Timothy Patton Specialist · Pittsburgh, PA
- Jamie L. Rhoads, M.D. Dermatology · Murray, UT
- Richard H. Flowers IV, MD Dermatology · Charlottesville, VA
- Teri Greiling, MD, PHD Dermatology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Utah Hospital and Clinics, UT $783,950
- Ohsu Hospital and Clinics, OR $53,991
- Mayo Clinic Hospital, AZ $51,654
- The University of North Carolina at Chapel Hill $20,240
- University of Miami $16,333
- University of Connecticut Health Center $14,103
- University of Iowa Hospital & Clinics, IA $12,170
- Tufts Medical Center, MA $4,279
- University of Michigan Health System, MI $1,596
- University of Virginia Medical Center, VA $495
- University of Alabama Hospital, AL $482
- Dermatologic Surgery Specialists PC $439
- University of Pittsburgh Physicians $318
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.